Brief: Longeveron Announces Additional Positive Clinical Data And Imaging Biomarker Results From The Clear Mind Phase 2A Trial Of Lomecel-B™
20/12/2023 13:06
Dec 20 (Reuters) - Longeveron Inc LGVN.O :
* LONGEVERON ANNOUNCES ADDITIONAL POSITIVE CLINICAL DATA AND
IMAGING BIOMARKER RESULTS FROM THE CLEAR MIND PHASE 2A TRIAL OF
LOMECEL-B™ IN THE TREATMENT OF MILD ALZHEIMER’S DISEASE
* LONGEVERON INC - NEW CLINICAL DATA SHOWED THAT LOMECEL-B™
IMPROVED COGNITIVE FUNCTION IN MULTIPLE MEASURES IN A
DOSE-RESPONSE FASHION
* LONGEVERON INC: EXPANDED DATA SET REINFORCED EARLIER
TOP-LINE
FINDINGS SHOWING THAT PRIMARY SAFETY ENDPOINT WAS MET
* LONGEVERON INC: CLEAR MIND RESULTS SHOWED LOMECEL-B
APPEARED TO
DEMONSTRATE A POSITIVE BENEFIT/RISK PROFILE
Source text for Eikon: ID:nGNX9sn9d4
Further company coverage: LGVN.O
((Reuters.Briefs@thomsonreuters.com;))